Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Value-Based Care Topic Center

Featured

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
From Cancer Care Business Exchange
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024

Winston Wong, PharmD

Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Engaging Payers
How to Support the Adoption and Integration of Specialty Value-Based Care Models: A Conversation Across Multiple Stakeholders
02/09/2024
Lili Brillstein, MPH
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses...
02/09/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes
01/25/2024

Featuring David F. Lobach, MD, PhD

Featuring David F. Lobach, MD, PhD ...
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters
01/24/2024

Featuring Mary E. Cooley, PhD, RN, FAAN

Featuring Mary E. Cooley, PhD, RN, FA...
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
Expanding Access to Care Through Academic-Community Cancer Care Collaboration
01/23/2024

Featuring Harlan Levine, MD

Featuring Harlan Levine, MD
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials
12/28/2023

Featuring Kianta Key

Featuring Kianta Key
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
News
CPC & CBEx Keynote Session: How Do We Define Value-Based Oncology Care?
10/07/2023

Brandon Twyford

Brandon Twyford
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways

Expert Insights

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024

Winston Wong, PharmD

Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes
01/25/2024

Featuring David F. Lobach, MD, PhD

Featuring David F. Lobach, MD, PhD ...
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters
01/24/2024

Featuring Mary E. Cooley, PhD, RN, FAAN

Featuring Mary E. Cooley, PhD, RN, FA...
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
Expanding Access to Care Through Academic-Community Cancer Care Collaboration
01/23/2024

Featuring Harlan Levine, MD

Featuring Harlan Levine, MD
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials
12/28/2023

Featuring Kianta Key

Featuring Kianta Key
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
Theresa Dreyer, MPH
Videos
Perspective on Lessons Learned from Academic Practices Participating in OCM
06/30/2023

Featuring Theresa Dreyer, MPH

Featuring Theresa Dreyer, MPH
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based...
06/30/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023

Jacqlyn Riposo, MBA; Tom Valuck, MD, JD

Jacqlyn Riposo, MBA; Tom Valuck, MD, ...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 2)
05/20/2024
Michael Kolodziej, MD
John Hennessy, MBA
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part...
05/20/2024
Cancer Care Business Exchange
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways

Newsfeed

News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
News
CPC & CBEx Keynote Session: How Do We Define Value-Based Oncology Care?
10/07/2023

Brandon Twyford

Brandon Twyford
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways
News
Regional Variations Detected in Clinical Trial Outcomes in Oncology
09/13/2022

Yvette C Terrie

Yvette C Terrie
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on...
09/13/2022
Journal of Clinical Pathways
News
Cancer Care Spending in the US May Not Be Proportionate With Better Cancer Outcomes
09/01/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent...
09/01/2022
Journal of Clinical Pathways
News
Trends for Identifying Regulator and Payer Evidence Needs in Development of Oncology Drugs
08/26/2022

Yvette C Terrie

Yvette C Terrie
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of...
08/26/2022
Journal of Clinical Pathways
News
Labcorp Announces Spinoff of Clinical Development Business
08/26/2022

Yvette C Terrie

Yvette C Terrie
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
Projected Medicare Basic Part D Average Premium for 2023 Announced
08/26/2022

Yvette C Terrie

Yvette C Terrie
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
Examining Therapy Utilization and Quality of Care at Skilled Nursing Facilities Under Patient Driven Payment Model
08/16/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Defining the Notion of Value in Oncology Treatment
07/07/2022

Ellen Kurek

Ellen Kurek
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses...
07/07/2022
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Interactive Features

Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Discussing Treatment Costs With Patients
03/12/2021
03/12/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement